Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker Commons There are currently 51 users online Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us
|
microarrayQIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological DataQIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of Ingenuity Systems, Inc., the leading provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data. Ingenuity, a privately-held U.S. company based in California’s Silicon Valley, has created the market leading expertly curated knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems.
Tags:
Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular OncologyRosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, recently announced that a manuscript regarding the development and validation of the Company's microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology. Yael Spector, a scientist from Rosetta Genomics, and Dr. Eddie Fridman , a pathologist and an expert in urological pathology from Sheba Medical Center in Tel-Hashomer, Israel, are the lead authors on the manuscript.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form. Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|
